Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI), an SEC filer in Biological Products, (No Diagnostic Substances), closed at $2.51, -6.3%, on 2026-08-28, with a market cap of $3.7B as of 2026-08-27, a return on equity of -91.9% and a net margin of -633.6%. Institutional ownership, earnings history and filed financials are on the tabs below.
| # | Holder | Shares | Value | % of shares out | Δ QoQ |
|---|---|---|---|---|---|
| 1 | XTX Topco Ltd | 24,04124,041 | $13,283 | 0.00% | TRIM -12% |
| 2 | RHUMBLINE ADVISERS | 1,8781,878 | $1,037 | 0.00% | — |
| 3 | UBS Group AG | 919919 | $524 | 0.00% | TRIM -47% |
| 4 | MORGAN STANLEY | 5858 | $33 | 0.00% | — |
Ranked by each filer’s own reported value, not shares.
| Biggest buyers | Δ shares | Δ value | |
|---|---|---|---|
| No filer increased its position this quarter. | |||
| Biggest sellers | Δ shares | Δ value | |
|---|---|---|---|
| CITADEL ADVISORS LLC | −34,562 | $19,700 | CLOSE |
| Virtu Financial LLC | −15,409 | $8,783 | CLOSE |
| XTX Topco Ltd | −3,253 | $1,854 | TRIM |
| NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO | −1,000 | $570 | CLOSE |
| UBS Group AG | −829 | $473 | TRIM |
Prior quarter split-rebased · 13Fs are long, US-listed only.
| Holder | 2024-Q4 | 2025-Q1 | 2025-Q2 | 2025-Q3 | 2025-Q4 | 2026-Q1 | Latest value |
|---|---|---|---|---|---|---|---|
| XTX Topco Ltd | — | — | — | — | 27K | 24K | $13,283 |
| RHUMBLINE ADVISERS | 2K | 2K | 3K | 4K | 2K | 2K | $1,037 |
| UBS Group AG | 23K | 15K | 12K | 8 | 2K | 919 | $524 |
| MORGAN STANLEY | 255 | 255 | 255 | 245 | 58 | 58 | $33 |
Green = added, red = trimmed, grey = held; a dash is a quarter with no 13F on file — a gap, not an exit.
Breaks = no 13F that quarter.
Short interest has its own tab now — open SI →
SEC Form 13F · ~10,250 filers, 10y · long-only, US-listed, filed ≤45d after quarter-end.
| Holder | % of class | Type | As of | |
|---|---|---|---|---|
| LCK JNK 1 LLC | 6.33% | Passive | 2026-04-27 | SEC → |
SEC Schedule 13D/G XML · group aggregate.
